{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:31Z","timestamp":1793727871672,"version":"4.6.1"},"reference-count":278,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semnuclmed.2022.11.001","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T01:29:42Z","timestamp":1670981382000},"page":"320-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["PET\/CT in Non-Hodgkin Lymphoma: An Update"],"prefix":"10.1053","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-8220","authenticated-orcid":false,"given":"Lucia","family":"Zanoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-2052","authenticated-orcid":false,"given":"Davide","family":"Bezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paccagnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-6064","authenticated-orcid":false,"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0001","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines\u00ae insights: b-cell lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109793","article-title":"Overview and recent advances in PET\/CT imaging in lymphoma and multiple myeloma","volume":"141","author":"Zanoni","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0003","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1002\/cncr.33772","article-title":"Positron emission tomography\/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update","volume":"127","author":"Juweid","year":"2021","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma - An evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0005","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1148\/radiol.2018181519","article-title":"Effect of PET\/CT on the management and outcomes of participants with hodgkin and aggressive non-hodgkin lymphoma: A multicenter registry","volume":"290","author":"Metser","year":"2019","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0007","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0008","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma","volume":"54","author":"Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0009","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0010","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1007\/s00259-020-04913-9","article-title":"Diagnostic accuracy of positron emission tomography\/computed tomography-driven biopsy for the diagnosis of lymphoma","volume":"47","author":"Broccoli","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0011","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0012","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0013","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/10428194.2019.1581931","article-title":"Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: A large retrospective analysis in 96 patients","volume":"60","author":"Broccoli","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0014","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00259-019-04323-6","article-title":"Role of 18F-FLT PET\/CT in suspected recurrent or residual lymphoma: Final results of a pilot prospective trial","volume":"46","author":"Zanoni","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.rcl.2004.08.008","article-title":"Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas","volume":"42","author":"Kumar","year":"2004","journal-title":"Radiol Clin North Am"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0016","first-page":"5","article-title":"Staging and response assessment in lymphomas: The new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0017","article-title":"Application of the lugano classification for initial evaluation, staging, and response assessment of hodgkin and Non-Hodgkin lymphoma: the prolog consensus initiative (part 2- technical)","author":"Ricard","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0018","article-title":"Application of the lugano classification for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin Lymphoma: the prolog consensus initiative (PART 1- CLINICAL)","author":"Ricard","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0019","first-page":"312","article-title":"18F-FDG PET\/CT in the clinical management of patients with lymphoma","volume":"36","author":"Tamayo","year":"2017","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","article-title":"Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus","volume":"53","author":"Meignan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0021","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0022","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1007\/s00259-022-05683-2","article-title":"Clinical and pathological predictors for FDG-PET\/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study","volume":"49","author":"Kagan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0023","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/bloodadvances.2017013698","article-title":"Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma","volume":"2","author":"Qi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0024","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.23638","article-title":"Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database","volume":"89","author":"Castillo","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/RCT.0000000000000485","article-title":"Systematic review on the additional value of 18F-Fluoro-2-Deoxy-D-glucose positron emission tomography in staging follicular lymphoma","volume":"41","author":"Adams","year":"2017","journal-title":"J Comput Assist Tomogr"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0026","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/cancers14030750","article-title":"Is There a Role for [18F]FDG PET-CT in staging MALT lymphoma?","volume":"14","author":"Cohen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0027","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.clml.2019.10.006","article-title":"18F-FDG PET\/CT or PET role in MALT lymphoma: An open issue not yet solved-a critical review","volume":"20","author":"Albano","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0028","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2967\/jnumed.120.259242","article-title":"Diagnostic contribution of contrast-enhanced CT as compared with unenhanced low-dose CT in PET\/CT staging and treatment response assessment of 18F-FDG-avid lymphomas: A prospective study","volume":"62","author":"Marchetti","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0029","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11912-021-01127-6","article-title":"Current role of functional imaging in the management of lymphoma","volume":"23","author":"Cheson","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0030","article-title":"18f-fluorodeoxyglucose positron emission tomography versus bone marrow biopsy for the evaluation of bone marrow infiltration in newly diagnosed lymphoma patients","volume":"73","author":"Aguado-V\u00e1zquez","year":"2020","journal-title":"Rev Invest Clin"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0031","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1007\/s00259-021-05348-6","article-title":"FDG PET\/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: Results from the prospective, multicenter PETAL and OPTIMAL>60 trials","volume":"48","author":"Kaddu-Mulindwa","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0032","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Sehn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0033","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.2014.58.7360","article-title":"Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma","volume":"33","author":"Adams","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0034","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00259-008-1021-9","article-title":"Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate","volume":"36","author":"Paone","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170299","article-title":"PET\/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma","volume":"12","author":"El Karak","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0036","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ajh.23760","article-title":"The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement","volume":"89","author":"Jackson","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0037","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2967\/jnumed.112.114710","article-title":"In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy","volume":"54","author":"Berthet","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0038","doi-asserted-by":"crossref","first-page":"550.e19","DOI":"10.1016\/j.crad.2021.02.023","article-title":"Prognostic significance of bone marrow 2-[18F]-fluoro-2-deoxy-d-glucose uptake in diffuse large B-cell lymphoma: Relation to iliac crest biopsy results","volume":"76","author":"Lim","year":"2021","journal-title":"Clin Radiol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0039","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12288-020-01284-x","article-title":"Comparison of bone marrow involvement with bone marrow biopsy and PET-CT and evaluation of any effects on survival in patients diagnosed with hodgkin and non-hodgkin lymphoma","volume":"37","author":"G\u00f6\u00e7er","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0040","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1080\/10428194.2020.1798950","article-title":"Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era - Tissue remains the issue","volume":"61","author":"Sundaram","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0041","article-title":"18F-FDG PET\/CT plays a limited role in replacing bone marrow biopsy for newly diagnosed advanced-stage patients with extranodal natural killer\/T-cell lymphoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0042","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","article-title":"Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: A systematic review","volume":"48","author":"Frood","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0043","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0044","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.18016","article-title":"Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?","volume":"197","author":"El-Galaly","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0046","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0047","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00277-021-04498-9","article-title":"Clinical impact of extranodal metabolic tumor volume in 240 diffuse large B cell lymphoma patients with extranodal involvement","volume":"100","author":"Song","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0048","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2967\/jnumed.119.238923","article-title":"Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: Which method is most successful? A study on behalf of the PETRA consortium","volume":"62","author":"Barrington","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0049","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.4446","article-title":"CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival","volume":"235","author":"Moreno","year":"2015","journal-title":"J Pathol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0050","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","article-title":"18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma","volume":"49","author":"Eertink","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0051","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0052","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome","volume":"61","author":"Cottereau","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0053","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.3390\/cancers13163998","article-title":"New Approaches in characterization of lesions dissemination in DLBCL patients on baseline PET\/CT","volume":"13","author":"Cottereau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0054","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s12149-021-01609-4","article-title":"18F-FDG cerebellum\/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma","volume":"35","author":"Morland","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0055","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-Cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0056","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2020.263194","article-title":"Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma","volume":"107","author":"Rossi","year":"2022","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-022-03418-5","article-title":"High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma","author":"Kuroki","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0058","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.2147\/CMAR.S216445","article-title":"Prognostic values of baseline, interim and end-of therapy 18F-FDG PET\/CT in patients with follicular lymphoma","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0059","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: A LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0060","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: Distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0061","first-page":"202","article-title":"Clinical application of [18F]FDG PET\/CT in follicular lymphoma","volume":"41","author":"D\u00edaz-Silv\u00e1n","year":"2022","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0062","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0063","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/MNM.0000000000001279","article-title":"18F-FDG PET\/computed tomography may predict the outcome of newly diagnosed indolent non-Hodgkin lymphoma in patients managed with initial \u201cwatch-and-wait\u201d approach","volume":"41","author":"Luo","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0064","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1007\/s00330-022-08624-7","article-title":"Baseline [18F]FDG PET\/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial \u201cwatch-and-wait\u201d approach","volume":"32","author":"Yang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0065","article-title":"Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden","author":"Leccisotti","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0066","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3324\/haematol.2019.223016","article-title":"Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project","volume":"105","author":"Bailly","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0067","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/jcm11051210","article-title":"Prognostic role of pre-treatment metabolic parameters and sarcopenia derived by 2-[18F]-FDG PET\/CT in elderly mantle cell lymphoma","volume":"11","author":"Albano","year":"2022","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0068","article-title":"Prognostic value of heterogeneity index derived from baseline 18F-FDG PET\/CT in mantle cell lymphoma","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0069","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/j.clml.2020.06.018","article-title":"Prognostic value of 18F-FDG PET\/CT metabolic parameters in splenic marginal zone lymphoma","volume":"20","author":"Albano","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0070","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11307-022-01703-7","article-title":"Role of radiomics-based baseline PET\/CT imaging in lymphoma: Diagnosis, prognosis, and response assessment","volume":"24","author":"Jiang","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0071","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00330-020-06815-8","article-title":"Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy","volume":"30","author":"Aide","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0072","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/MNM.0000000000001447","article-title":"Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma","volume":"42","author":"Coskun","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0073","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.3390\/diagnostics11010036","article-title":"Prognostic value of baseline radiomic features of 18F-FDG PET in patients with diffuse large B-cell lymphoma","volume":"11","author":"Lue","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0074","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s00259-021-05572-0","article-title":"A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET\/CT","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0075","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/cancers14071711","article-title":"Discovery of pre-treatment FDG PET\/CT-derived radiomics-based models for predicting outcome in diffuse large B-cell lymphoma","volume":"14","author":"Frood","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0076","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-022-05916-4","article-title":"Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET\/CT radiomics features","author":"Eertink","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0077","first-page":"269","article-title":"Radiomics analysis for differentiating of cervical lymphadenopathy between cancer of unknown primary and malignant lymphoma on unenhanced computed tomography","volume":"84","author":"Tomita","year":"2022","journal-title":"Nagoya J Med Sci"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0078","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1007\/s00259-019-04420-6","article-title":"Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma","volume":"46","author":"Mayerhoefer","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0079","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/diagnostics12061330","article-title":"Radiomics in oncological PET Imaging: A systematic review-part 2, infradiaphragmatic cancers, blood malignancies, melanoma and musculoskeletal cancers","volume":"12","author":"Morland","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cpet.2021.09.006","article-title":"Artificial intelligence in lymphoma PET imaging: A scoping review (current trends and future directions)","volume":"17","author":"Hasani","year":"2022","journal-title":"PET Clin"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0081","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cpet.2019.03.002","article-title":"PET-derived quantitative metrics for response and prognosis in lymphoma","volume":"14","author":"Kostakoglu","year":"2019","journal-title":"PET Clin"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0082","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s00259-020-05080-7","article-title":"Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET\/CT for total metabolic tumour volume prediction using a convolutional neural network","volume":"48","author":"Blanc-Durand","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0083","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1007\/s00330-022-08573-1","article-title":"Deep learning-based tumour segmentation and total metabolic tumour volume prediction in the prognosis of diffuse large B-cell lymphoma patients in 3D FDG-PET images","volume":"32","author":"Jiang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0084","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/diagnostics12020417","article-title":"Deep learning approach to automatize TMTV calculations regardless of segmentation methodology for major FDG-avid lymphomas","volume":"12","author":"Revailler","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0085","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.121.263501","article-title":"18F-FDG PET maximum intensity projections and artificial intelligence: A win-win combination to easily measure prognostic biomarkers in DLBCL patients","author":"Girum","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0086","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.121.263598","article-title":"Distinction of lymphoma from sarcoidosis at FDG PET\/CT - evaluation of radiomic-feature guided machine learning versus human reader performance","author":"Lovinfosse","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0087","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymeth.2020.06.020","article-title":"Functional imaging using radiomic features in assessment of lymphoma","volume":"188","author":"Mayerhoefer","year":"2021","journal-title":"Methods"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0088","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.3390\/cancers13205222","article-title":"FDG-PET\/CT in lymphoma: Where do we go now?","volume":"13","author":"Y","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0089","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11899-020-00577-2","article-title":"Radiogenomics and its role in lymphoma","volume":"15","author":"Khan","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0091","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.110.080556","article-title":"Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: Importance of the reference background","volume":"51","author":"Itti","year":"2010","journal-title":"J Nucl Med"},{"issue":"S1 suppl 1","key":"10.1053\/j.semnuclmed.2022.11.001_bib0092","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0093","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0094","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0095","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0096","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s13139-015-0368-7","article-title":"FDG PET\/CT response assessment criteria for patients with Hodgkin's and non Hodgkin's lymphoma at end of therapy: A multiparametric approach","volume":"50","author":"Metser","year":"2016","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0097","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00259-016-3390-9","volume":"43","author":"Fallanca","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0098","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed to mography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0099","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/028418699432969","article-title":"Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest","volume":"38","author":"Bangerter","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0100","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1053\/j.semnuclmed.2022.11.001_bib0101","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hon.2438_45","article-title":"End of treatment PET-CT predicts progression-free survival in DLBCL after first-line treatment: Results from the phase III GOYA study","volume":"35","author":"Kostakoglu","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0102","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/10428194.2019.1663422","article-title":"Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: Biopsy, treat or observe?","volume":"61","author":"Novo","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0038-1623988","article-title":"Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma","volume":"40","author":"Cremerius","year":"2001","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0104","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bjh.13831","article-title":"Delineating outcomes of patients with diffuse large B cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis","volume":"172","author":"Bishton","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0105","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with difuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0106","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","article-title":"Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma","volume":"118","author":"Micallef","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0107","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12032-017-0885-6","article-title":"Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients","volume":"34","author":"Kanemasa","year":"2017","journal-title":"Med Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0108","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","article-title":"End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: Results from GOYA","volume":"5","author":"Kostakoglu","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0109","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0110","doi-asserted-by":"crossref","unstructured":"Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. 2015.","DOI":"10.1200\/JCO.2014.60.2383"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0111","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.15619","article-title":"Cell-of-origin in diffuse large B-cell lymphoma: Findings from the UK's population-based Haematological Malignancy Research Network","volume":"185","author":"Painter","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0112","doi-asserted-by":"crossref","first-page":"e804","DOI":"10.1016\/j.clml.2022.04.010","article-title":"Baseline total metabolic tumor volume is prognostic for refractoriness to immunochemotherapy in DLBCL: Results from GOYA","volume":"22","author":"Ruiz","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0113","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12149-020-01542-y","article-title":"The prognostic role of end-of-treatment FDG-PET\/CT in diffuse large B cell lymphoma: A pilot study application of neural networks to predict time-to-event","volume":"35","author":"Annunziata","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0114","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0115","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0116","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B- Cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0117","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0118","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.16875","article-title":"FDG-PET\/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - Final result of a UK National Cancer Research Institute prospective study","volume":"192","author":"Mikhaeel","year":"2021","journal-title":"Br J Hae- matol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0119","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): A multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0120","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/10428194.2017.1339877","article-title":"Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores","volume":"59","author":"Kim","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2016.1277384","article-title":"Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma","volume":"58","author":"Fan","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0122","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cam4.2404","article-title":"Interim PET\/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0123","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/ajh.23267","article-title":"The impact of baseline and interim PET\/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma","volume":"87","author":"Park","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0124","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hon.2805","article-title":"Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38\/07 clinical trial","volume":"38","author":"Zucca","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0125","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ejca.2010.12.027","article-title":"Prognostic sig- nificance of interim (1)(8)F-FDG PET\/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma","volume":"47","author":"Yang","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0126","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood.2019003277","article-title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: Results from the CALGB 50303 clinical trial","volume":"135","author":"Schoder","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0127","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","article-title":"Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: A systematic review and meta-analysis","volume":"46","author":"Burggraaff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0128","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: A comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0129","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ejh.13684","article-title":"Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma","volume":"107","author":"Wight","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0130","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.121.262205","article-title":"HOVON imaging working group and the HOVON lymphoma working group. 18F-FDG PET Improves baseline clinical predictors of response in diffuse large B-Cell lymphoma: The HOVON-84 study","volume":"63","author":"Burggraaff","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.120.244145","article-title":"Interim PET evaluation in diffuse large B-Cell lymphoma using published recommendations: Comparison of the Deauville 5-point scale and the \u0394SUVmax method","volume":"62","author":"Rekowski","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0132","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2967\/jnumed.119.231621","article-title":"Combined visual and semiquantitative evaluation improves outcome prediction by early midtreatment 18F-FDG PET in diffuse large B-Cell lymphoma","volume":"61","author":"Gy\u00f6rke","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0133","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2967\/jnumed.120.255034","article-title":"Interim PET in diffuse large B-cell lymphoma","volume":"62","author":"Kurch","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0134","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00259-021-05581-z","article-title":"The prognostic value of end-of-treatment FDG-PET\/CT in diffuse large B cell lymphoma: Comparison of visual Deauville criteria and a lesion-to-liver SUVmax ratio-based evaluation system","volume":"49","author":"Li","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0135","doi-asserted-by":"crossref","first-page":"e922","DOI":"10.1016\/j.clml.2021.06.016","article-title":"The Role of Interim PET\/CT on survival in diffuse large B cell lymphoma","volume":"21","author":"Uluk\u00f6yl\u00fc-Meng\u00fc\u00e7","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0136","article-title":"The prognostic utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography-based analyses of metabolic response rates in newly diagnosed diffuse large B cell lymphoma patients","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0137","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0138","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0139","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0140","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers14041018","article-title":"Integration of baseline metabolic parameters and mutational profiles predicts long-term response to first-line therapy in DLBCL patients: A post hoc analysis of the SAKK38\/07 study","volume":"14","author":"Genta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0141","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-Cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0142","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11307-022-01703-7","article-title":"Role of radiomics-based baseline PET\/CT imaging in lymphoma: Diagnosis, prognosis, and response assessment","volume":"24","author":"Jiang","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0143","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0144","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bjh.13036","article-title":"Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial","volume":"167","author":"Pardal","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0145","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3109\/10428194.2013.862242","article-title":"Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma","volume":"55","author":"Stewart","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0146","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","article-title":"Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG- PET scanning","volume":"15","author":"Kasamon","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0147","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0148","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood.2020008750","article-title":"Obinutuzumab vs rituximab for advanced DLBCL: A PET-guided and randomized phase 3 study by LYSA","volume":"137","author":"Gouill","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0149","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2021013998","article-title":"Limited-stage diffuse large B-cell lymphoma","volume":"139","author":"Hawkes","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0150","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-07-793984","article-title":"LYSA Group. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","author":"Lamy","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0151","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed ther- apy for patients with limited-stage diffuse large B-cell lymphoma: Results of Intergroup National Clinical Trials Network Study S1001 [published correction appears","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin.Oncol"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2022.11.001_bib0152","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2019-128722","article-title":"Long-term follow-up of a PET-guided approach to treatment of limited-stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC)","volume":"134","author":"Sehn","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0153","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hon.5_2879","article-title":"Early positron emission tomography response-adapated treatment in localised diffuse large B-cell lymphoma (aaIPI50): results of the phase 3 LYSA LNH 09-1B trial","volume":"39","author":"Bologna","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2022.11.001_bib0154","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12885-022-09486-4","article-title":"Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET\/CT: An analysis of a prospective trial","volume":"22","author":"Jin","year":"2022","journal-title":"BMC Cancer"},{"issue":"15 suppl","key":"10.1053\/j.semnuclmed.2022.11.001_bib0155","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2017.35.15_suppl.7506","article-title":"Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL","volume":"35","author":"Pfreundschuh","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0156","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0157","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.2020008740","article-title":"PET response-guided radiotherapy for advanced DLBCL?","volume":"137","author":"Wirth","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0158","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.3324\/haematol.2020.249680","article-title":"Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: A comprehensive meta-analysis","volume":"106","author":"Berger","year":"2021","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0159","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0160","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00259-013-2441-8","article-title":"PET\/CT assessment in follicular lymphoma using standardized criteria: Central review in the PRIMA study","volume":"41","author":"Tychyj-Pinel","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0161","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-linet herapy in patients with follicular lymphoma: A pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0162","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end- of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): Secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0163","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: An individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0164","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/bjh.18217","article-title":"End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma","volume":"198","author":"Dixon","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0165","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in High-Tumor-Burden follicular lymphoma: A pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0166","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0167","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/bloodadvances.2020004051","article-title":"Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma","volume":"5","author":"Nath","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0168","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0169","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","article-title":"Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"101","author":"Luminari","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0170","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","article-title":"Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial","volume":"20","author":"Galimberti","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1053\/j.semnuclmed.2022.11.001_bib0171","first-page":"171","article-title":"Metabolic (PET) and MRD response confer reduced risk of progression or death in patients treated within the phase III Gallium study","volume":"2","author":"Pott","year":"2018","journal-title":"HemaSphere"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0172","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Fondazione Italiana Linfomi. Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: The FOLL12 Study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0173","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.21.02477","article-title":"Response-adapted therapy in follicular lymphoma: At the threshold of a precision approach","volume":"40","author":"Casulo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0174","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-014-2227-5","article-title":"Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma","volume":"94","author":"Tomita","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.112.110262","article-title":"Prognostic value of interim and posttherapy 18F-FDG PET\/CT in patients with mature T-cell and natural killer cell lymphomas","volume":"54","author":"Li","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0176","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma","volume":"54","author":"Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0177","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","article-title":"Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma","volume":"15","author":"Jung","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0178","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-oftreatment PET\/CT in peripheral T-cell lymphomas: A review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0179","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/annonc\/mdq415","article-title":"18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T\/NK lymphomas: A study from the GOELAMS group","volume":"22","author":"Cahu","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0180","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1634\/theoncologist.2013-0463","article-title":"Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma","volume":"19","author":"Pellegrini","year":"2014","journal-title":"Oncologist"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0181","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1007\/s00259-018-4093-1","article-title":"A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score","volume":"45","author":"Yhim","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0182","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0183","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0184","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.14473","article-title":"How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: Current practice and a glimpse into the future","volume":"176","author":"Schmitz","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0185","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0186","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0187","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1038\/bcj.2017.39","article-title":"The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma","volume":"7","author":"Eslick","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0188","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/10428194.2016.1236380","article-title":"Value of interim FDG PET\/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma","volume":"58","author":"Moon","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0189","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1038\/bcj.2016.2","article-title":"The prognostic value of interim and end-of-treatment PET\/CT in patients with newly diagnosed peripheral T-cell lymphoma","volume":"6","author":"Ham","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0190","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hon.2697","article-title":"A. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial","volume":"38","author":"Schmitz","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0191","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-021-00827-1","article-title":"Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma","volume":"11","author":"Kurch","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0192","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1200\/JCO.2020.38.15_suppl.8041","article-title":"Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: A subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA)","volume":"38","author":"Held","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0193","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with doseadjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0194","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following doseadjusted EPOCH-R: A paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: The emerging standard of care","volume":"17","author":"Vassilakopoulos","year":"2012","journal-title":"Oncologist"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0196","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0197","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211048959","article-title":"Current and emerging treatment options in primary mediastinal B-cell lymphoma","volume":"12","author":"Fakhri","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0198","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2016.09.031","article-title":"Positron emission tomography\/computed tomography assessment after immunochemotherapy and irradiation using the lugano classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma","volume":"97","author":"Ceriani","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0199","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00277-021-04421-2","article-title":"Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: Impact on outcomes and radiotherapy strategies","volume":"100","author":"Vassilakopoulos","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0200","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","article-title":"Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: A LYSA study","volume":"5","author":"Camus","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0201","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s00259-017-3758-5","article-title":"Poor predictive value of positive interim FDG-PET\/CT in primary mediastinal large B-cell lymphoma","volume":"44","author":"Lazarovici","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0202","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00259-018-3946-y","article-title":"Interim FDG PET\/CT in primary mediastinal diffuse large B-cell lymphoma: Really almost useless procedure?","volume":"45","author":"Proch\u00e1zka","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0203","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s00259-021-05310-6","article-title":"Deauville score evaluation of interim PET\/CT in primary mediastinal large B-cell lymphoma","volume":"48","author":"Qin","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0204","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood-2014-12-616474","article-title":"Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma","volume":"126","author":"Ceriani","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0205","article-title":"Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography\/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma","volume":"50","author":"Liu","year":"2022","journal-title":"J Int Med Res"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0206","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2019.05.010","article-title":"Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis","volume":"141","author":"Adams","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0207","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0208","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00432-010-0759-1","article-title":"The clinical significance of 18F-FDG-PET\/CT in early detection of second primary malignancy in cancer patients","volume":"136","author":"Xu","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0209","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038312","article-title":"Longitudinal exploration of cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma: Protocol for a feasibility study","volume":"10","author":"Gates","year":"2020","journal-title":"BMJ Open"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0210","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1080\/10428194.2021.1941936","article-title":"Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation","volume":"62","author":"Mou","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13244-019-0705-y","article-title":"Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: What every radiologist should know","volume":"10","author":"Alessandrino","year":"2019","journal-title":"Insights Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0212","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0213","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma","volume":"23","author":"Sch\u00f6der","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0214","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00259-021-05626-3","article-title":"Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET\/CT features","volume":"49","author":"de Jesus","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0215","article-title":"FDG-PET\/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma","author":"Rajam\u00e4ki","year":"2022","journal-title":"Cancer Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0216","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17474086.2020.1690987","article-title":"Histological transformation in malignant lymphoma: A possible role of PET\/CT and circulating tumor DNA as noninvasive diagnostic tools","volume":"13","author":"Ohmoto","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0217","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/ejh.12837","article-title":"Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: Systematic review and meta-analysis","volume":"98","author":"Adams","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0218","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: Final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0219","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.semnuclmed.2021.01.001","article-title":"FDG PET for assessment of autologous stem cell transplantation","volume":"51","author":"Jacene","year":"2021","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0220","first-page":"989","article-title":"Ultrasound-guided core-needle biopsy is effective in the initial diagnosis of lymphoma patients","volume":"83","author":"Zinzani","year":"1998","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0221","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/230949901302100218","article-title":"Computed tomography-guided core needle biopsy versus incisional biopsy in diagnosing musculoskeletal lesions","volume":"21","author":"Kiatisevi","year":"2013","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0222","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.surge.2014.09.002","article-title":"Outcome of image-guided biopsies: Retrospective review of the West of Scotland musculoskeletal oncology service","volume":"14","author":"Ferguson","year":"2016","journal-title":"Surgeon"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0223","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MNM.0000000000000780","article-title":"Post-therapy lesions in patients with non-Hodgkin's lymphoma characterized by 18F-FDG PET\/CT-guided biopsy using automated robotic biopsy arm","volume":"39","author":"Radhakrishnan","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0224","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2022.11.001_bib0225","article-title":"Durvalumab (anti PD-L1) as monotherapy or in combination therapy for relapsed\/refractory (r\/r) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A subgroup analysis from the phase 1\/2 fusion NHL-001 global multicenter trial","volume":"134","author":"Casulo","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0226","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2022.11.001_bib0227","article-title":"Immune priming with single-agent nivolumab followed by combined nivolumab & rituximab is safe and efficacious for first-line treatment of follicular lymphoma; interim analysis of the \u20181st FLOR\u2019 study","volume":"134","author":"Barraclough","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0228","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.74_2629","article-title":"Efficacy and safety of obinutuzumab\u202f+\u202flenalidomide\u202f+\u202fatezolizumab in patients with relapsed or refractory follicular lymphoma: Primary analysis of a phase 1B\/2 trial","volume":"37","author":"Morschhauser","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0229","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0230","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"Supplement1, abstract 467","key":"10.1053\/j.semnuclmed.2022.11.001_bib0231","article-title":"A phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0232","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hemat & Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0233","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0234","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clinical Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of response and progression to immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educational Book"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0236","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0237","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor","volume":"59","author":"Dercle","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0238","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and PET response in lymphoma during immunotherapy 33 refractory Hodgkin lymphoma: A series from lYsa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0239","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/10428194.2018.1488254","article-title":"18F-FDG PET\/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors","volume":"6","author":"Castello","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.18620\/ctt-1866-8836-2019-8-4-41-48","article-title":"Nivolumab in pediatric Hodgkin's lymphoma","volume":"8","author":"Kozlov","year":"2019","journal-title":"Cell Ther Transplant"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0241","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1148\/radiol.2020192056","article-title":"Performance of CT Compared with 18F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory hodgkin lymphoma","volume":"295","author":"Mokrane","year":"2020","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0242","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy: report on the EANM sympo- sium on immune modulation and recent review of the literature","volume":"46","author":"Aide","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0243","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0244","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0246","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0247","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: An analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transpl"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0248","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0249","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0251","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0252","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: An expert panel opinion from the American Society for transplantation and cellular therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0253","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0254","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0255","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0256","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00259-021-05551-5","article-title":"[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: A practical approach of reporting pre- and post-treatment studies","volume":"49","author":"Cohen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0257","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0258","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0259","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713577","article-title":"Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in non-hodgkin lymphoma","volume":"11","author":"Hong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0260","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0261","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/S2352-3026(20)30065-X","article-title":"Molecular imaging in lymphoma beyond 18F-FDG-PET: Understanding the biology and its implications for diagnostics and therapy","volume":"7","author":"Kahle","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0262","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/cancers14030626","article-title":"Targeted drug delivery and theranostic strategies in malignant lymphomas","volume":"14","author":"Etrych","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0263","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.2c00563","article-title":"Immuno-PET imaging and radioimmunotherapy of lymphomas","author":"Lee","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0264","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3390\/cancers14143488","article-title":"Clinical applications of immuno-PET in lymphoma: A systematic review","volume":"14","author":"Triumbari","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0265","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.drudis.2021.11.019","article-title":"ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality","volume":"27","author":"Dun","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0266","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.3390\/cancers14153814","article-title":"The role of [68Ga]Ga-Pentixafor PET\/CT or PET\/MRI in lymphoma: A systematic review","volume":"14","author":"Albano","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0267","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","article-title":"Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET\/CT","volume":"62","author":"Duell","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0268","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7150\/thno.48620","article-title":"CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: Comparison with [18F]FDG-PET","volume":"11","author":"Mayerhoefer","year":"2021","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0269","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood.2021013239","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication","volume":"139","author":"Mayerhoefer","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0270","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2967\/jnumed.118.210997","article-title":"Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma","volume":"60","author":"Lapa","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0271","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/MNM.0000000000001465","article-title":"Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET\/CT in lymphomas: a preliminary analysis","volume":"42","author":"de Souza","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0272","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2967\/jnumed.121.262134","article-title":"Detecting fibroblast activation proteins in lymphoma using 68Ga-FAPI PET\/CT","volume":"63","author":"Jin","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0273","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s00259-021-05353-9","article-title":"18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: A multicenter study","volume":"48","author":"Minamimoto","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0274","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12149-015-1047-6","article-title":"18)F-FDG and (18)F-FLT PET\/CT imaging in the characterization of mediastinal lymph nodes","volume":"30","author":"Rayamajhi","year":"2016","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0972-3919.130274","article-title":"FLT PET-CT in evaluation of treatment response","volume":"29","author":"Sanghera","year":"2014","journal-title":"Indian J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0276","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2967\/jnumed.117.206920","article-title":"18F-Fludarabine PET for lymphoma imaging: First-in-humans study on DLBCL and CLL patients","volume":"59","author":"Chantepie","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0277","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.3390\/cancers12030601","article-title":"FDG-PET imaging for hodgkin and diffuse large B-cell lymphoma-An updated overview","volume":"12","author":"Voltin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.11.001_bib0278","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/joim.12813","article-title":"FDG-PET\/CT in the management of lymphomas: Current status and future directions","volume":"284","author":"El-Galaly","year":"2018","journal-title":"J Intern Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:40:22Z","timestamp":1757544022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":278,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0001299822000964"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.11.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT in Non-Hodgkin Lymphoma: An Update","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}